The circadian mechanism underlies daily rhythms in cardiovascular physiology and rhythm disruption is a major risk factor for heart disease and worse outcomes. However, the role of circadian rhythms is generally clinically unappreciated. Clock is a core component of the circadian mechanism and here we examine the role of Clock as a vital determinant of cardiac physiology and pathophysiology in aging. Clock Δ19/Δ19 mice develop agedependent increases in heart weight, hypertrophy, dilation, impaired contractility, and reduced myogenic responsiveness. Young Clock Δ19/Δ19 hearts express dysregulated mRNAs and miRNAs in the PTEN-AKT signal pathways important for cardiac hypertrophy. We found a rhythm in the Pten gene and PTEN protein in WT hearts; rhythmic oscillations are lost in Clock Δ19/Δ19 hearts. Changes in PTEN are associated with reduced AKT activation and changes in downstream mediators GSK-3β, PRAS40, and S6K1. Cardiomyocyte cultures confirm that Clock regulates the AKT signalling pathways crucial for cardiac hypertrophy. In old Clock Δ19/Δ19 mice cardiac AKT, GSK3β, S6K1 phosphorylation are increased, consistent with the development of age-dependent cardiac hypertrophy. Lastly, we show that pharmacological modulation of the circadian mechanism with the REV-ERB agonist SR9009 reduces AKT activation and heart weight in old WT mice. Furthermore, SR9009 attenuates cardiac hypertrophy in mice subjected to transverse aortic constriction (TAC), supporting that the circadian mechanism plays an important role in regulating cardiac growth. These findings demonstrate a crucial role for Clock in growth and renewal; disrupting Clock leads to age-dependent cardiomyopathy. Pharmacological targeting of the circadian mechanism provides a new opportunity for treating heart disease.
Circadian rhythms underlie daily variations in cardiovascular physiology including heart rate [1] , blood pressure [2] , and cardiac contractility [3] . Circadian rhythm disruption is a major risk factor for cardiovascular disease and is associated with adverse health consequences [4] [5] [6] . Recently there have been major advances in our understanding of daily rhythmicity, and it's relevance to the pathogenesis and treatment of cardiac hypertrophy and heart failure [3, [7] [8] [9] [10] [11] [12] . However, the underlying mechanisms responsible are generally clinically unappreciated, and their role in cardiac hypertrophy with aging is not known.
At the molecular level circadian clocks in all cells enable us to entrain to environmental cues and anticipate the differing physiologic demands of daily events, including those of the cardiovascular system. The circadian mechanism at its most basic level is a 24-hour transcription and translation loop present in virtually all cells including cardiomyocytes. The positive arm consists of a heterodimeric pairing of CLOCK and BMAL1, which bind to promoter E-boxes to induce expression of the repressors PERIOD (PER), CRYPTOCHROME (CRY), and REV-ERB. In the negative arm, PER and CRY are phosphorylated by CASEIN KINASE, inhibit their own transcription, and the 24-hour cycle begins again. There are many excellent reviews [13] [14] [15] [16] . The circadian mechanism also regulates daily patterns of tissue-specific factors, comprising~10% of the genes [17] [18] [19] and proteins [3] in the heart. CLOCK [20] is a core component of the circadian mechanism [21] [22] [23] and plays a role in regulating diurnal cardiac metabolism, contractile function, and gene and protein rhythms [1, 3, 4, 19] . However, whether CLOCK plays a role in cardiac growth and renewal, and conversely how disrupting CLOCK adversely affects heart structure and function, especially with aging is not known.
The risk of cardiovascular disease increases with age and the majority of heart failure diagnoses and deaths occur in those older than 70 years of age [24, 25] . Aging is associated with structural changes in the heart including myocardial thickening [26] , cardiomyocyte hypertrophy [27] , and cardiac fibrosis [28] . Moreover there is a decline in cardiac function [29, 30] , which is most apparent when the cardiovascular system is challenged, for example by exercise [31] . The average lifespan of humans has increased over the last 2 centuries [32] , Therefore understanding the mechanism that regulate age-dependent changes for healthy cardiovascular physiology are of clinical relevance, especially for maintaining high quality of life in the elderly population.
In this study we investigate the role of CLOCK in the pathophysiology of cardiac aging.
Here we use Clock Δ19/Δ19 mice which have a mutation in the Clock gene resulting in a protein incapable of transcriptional activation [22] . We demonstrate that Clock Δ19/Δ19 mice develop age-dependent cardiovascular disease. Moreover, we show that CLOCK is a key mediator of mRNAs and miRNAs in the PTEN-AKT signal pathways involved in cardiac hypertrophy. In vivo and in vitro experiments confirm that Clock regulates these signal pathways important for cellular hypertrophy. Moreover, pharmacological modulation of the circadian mechanism using the REV-ERB agonist SR9009 targets these pathways and attenuates cardiac hypertrophy in vivo. Identifying a direct role for CLOCK in cardiac remodeling could have therapeutic implications, especially for individuals subjected to circadian rhythm disruption such as shift works, individuals with sleep disorders, and in the aging population.
Materials and methods

Mice
Male homozygote Clock Δ19/Δ19 , heterozygote Clock Δ19/+ and wild type littermates on a congenic C57Bl/6J background [20] were obtained from our University of Guelph mouse breeding core, which sources its colony breeders from Jackson Laboratory [33] . Mice were housed under a 12-hour light (L):12-hour dark (D) cycle with standard chow and water provided ad libitum, and aged in the Central Animal Facilities at the University of Guelph. For sample collection animals were euthanized with isoflurane and cervical dislocation. For histology, hearts were perfused with 1 M KCl, fixed in 10% neutral buffered formalin for 24 h, and processed. Paraffin embedded hearts were sectioned at the level of the mid papillary and stained with Masson's trichrome or picrosirius red. For molecular studies tissues were frozen in liquid nitrogen and stored at − 80°C until assayed. The effects of SR9009 were assessed in 21 month old Clock Δ19/Δ19 and WT mice. Animals were administered the drug (100 mg/kg, i.p., b.i.d) or vehicle (15% cremophor) at ZT0 and ZT12 for 28 days. TAC mice were treated for 2 weeks with SR9009 following induction of pressure overload. For studies in P0 mice, hearts were collected at ZT07, two hearts were pooled per collection and a total of 6 hearts per genotype (n = 3 pooled samples) were used. All studies were approved by the University of Guelph Institutional Animal Care and Use Committee and in accordance with the guidelines of the Canadian Council on Animal Care.
Actigraphy
Wheel-running experiments were performed as described [34] . Individually housed mice were entrained to a diurnal 12:12 L:D cycle for 2 weeks, followed by transfer to constant darkness (circadian cycle, DD). Data were analyzed using ClockLab (ActiMetrics).
Radiotelemetry
PA-C10 murine telemetry probes (Data Sciences) were used to monitor and collect blood pressure and heart rate data from conscious, freely moving animals [7] . Data were acquired for 30 s every 5 min over 72 h, collated into 1-hour bins according to zeitgeber time, and averaged to yield a 24-hour plot.
Cardiac pathophysiology
Cardiac pathophysiology was performed using established techniques at 4, 8, 12, 18 and 21 months of age [33] . Serial echocardiography was done using a i13L 14 MHz linear-array transducer on a GE Vivid 7 Dimension ultrasound system. Hemodynamics were recorded in mice anesthetised under isoflurane, using a 1.2Fr pressure catheter (Transonic), and the ADI Power Lab system with Lab Chart 7.
Pressure myography
Cremaster skeletal muscle resistance arteries were isolated at ZT07 from 21 month old mice, canulated on glass micropipettes, and used for functional experiments as described [35] . For myogenic responsiveness, vessels were subject to 20 mm Hg stepwise increases in transmural pressure (from 20 to 100 mm Hg). The maximal diameter was measured under Ca 2+ -free conditions using the same stepwise protocol. Depolarization-induced vasoconstriction was determined using i) L-phenylephrine (PE, 1 nmol/L-10 μmol/L), or ii) KCl (60 mmol/L).
MicroRNA arrays and database
Total RNA was isolated from 4 and 21 month old WT and Clock
Δ19/Δ19
hearts collected at ZT06 using the miRNeasy Mini Kit (Qiagen). For miRNA microarray profiling, total RNA from 12 individual samples was used. Samples were digested (RNase Free DNase set, Qiagen), validated using RNA ScreenTape (RIN N 7; Agilent) and Nanodrop (260/280 ≥ 2.0; Thermo Scientific), and analyzed using the Affymetrix GeneChip miRNA 4.0 array which interrogates all mature miRNA sequences in miRBase v20 (G.E.O. Accession: GSE84151). Bioinformatics analyses were performed using the extraction software (v10.7.1.1) and GeneSpring Gx v11.5 (Agilent). Genome locations were from miRBase [36] . Validated target mRNAs were from Tarbase v7.0 [37] . KEGG pathways were from miRPath v2.0 [38] . All miRNAs N 50 Raw fluorescence units (RFUs) are listed our novel database at www. circadianmicrorna.com.
qRT-PCR
To determine mRNA expression profiles we used the Power SYBR Green RNA-to-CT one Step Kit (Life Technologies) on a ViiA7 real time PCR system (Applied Biosystems) using primers listed in Supplementary Table 6 . For studies with SR9009, the total RNA was isolated from hearts collected at ZT07 using the RNeasy kit (Qiagen). Relative expression was determined using the ΔΔCT method normalized to histone, as described [19] . To validation miRNA expression, qRT-PCR was performed using the qScript microRNA cDNA Synthesis Kit and the PerfeCTa SYBR Green Super Mix (Quanta Biosciences). All miRNA primers were purchased from Quanta Biosciences. Relative miRNA expression was determined using the ΔΔCT method, normalized to RNU6. qRT-PCR was performed using n = 3 individual hearts/group, and n = 2 technical duplicates.
Western blots
Protein extracts were prepared with CelLytic MT Cell Lysis Reagent (Sigma) supplemented with cOmplete protease and PhosSTOP phosphatase inhibitor cocktails (Roche). Lysates were subjected to SDS-PAGE and transferred to PVDF membrane (Bio-Rad) for immunoblotting. Primary antibodies were from Cell Signalling, as follows: phospho-PTEN (Ser380/Thr382/383) (#9554, 1:1000), PTEN (#9559; 1:1000), phospho-AKT (Ser473) (#4060; 1:1000), AKT (#4691; 1:1000), phospho-GSK-3β (Ser9) (#9323; 1:1000), GSK-3β (#9315; 1:1000), phospho-PRAS40 (Thr246) (#2997, 1:1000), PRAS40 (#2691; 1:1000). Loading was normalized to total protein using the Mem-code PVDF kit (Thermo Scientific). Proteins were visualized using SignalFire Elite ECL reagent (12757, Cell Signalling).
Comprehensive lab animal monitoring system (CLAMS)
CLAMS (Columbus Instruments) was used to monitor the metabolic parameters of 21 month old WT and Clock Δ19/Δ19 mice when administered SR9009 or vehicle (15% cremophor). Animals were acclimatized for 2 days in the CLAMS after which metabolic parameters were measured for 24 h.
Transverse aortic constriction
Young (8 weeks old), WT mice were subjected to transverse aortic constriction (TAC) to induce pressure overload cardiac hypertrophy, as described previously [7, 10, 39] . Briefly, mice were anesthetized with isoflurane and intubated. A thoracotomy was performed via an incision in the second intercostal space, and the transverse aorta distal to the left subclavian artery, was constricted using a 27-gauge needle. Sham mice underwent the same procedure but the aorta was not constricted.
Isolation, culture and treatment for hypertrophy of mouse cardiac myocytes
We isolated and cultured neonatal mouse cardiomyocytes using standard techniques [40] . Cells were plated at a density of 500 cells/mm 2 in 4-well LabTek chamber slides coated with collagen type I (Sigma). The following day cells were transferred to serum free media containing 0.1 mM BrdU for 24 h. On day 2 cells were treated with either IGF-1 (10 ng/ml, Sigma), or FBS (10%), or LiCl (20 mM) for 3 days, after which they were stained for α-actinin (A7811; Sigma 1:500) using Alexa Fluor 488 (A11029; Life Technologies, 1:500). Cell size was determined using Cell Profiler as described previously [41] .
Statistics
All values are mean ± SEM. The data were assessed for normal distribution and similar variance between groups using SigmaPlot 12 (Systat Software Inc.). We used a two-sided Student's t-test for comparisons between 2 groups. For the aging studies in mice, we used a two way ANOVA with Tukey post hoc, p b 0.05 are considered significant. Statistical analyses of 24 h gene rhythms was done using JTK_CYCLE v2.0 in R v3.1.2 [42] . JTK_CYCLE is used to identify rhythmic components and provide an estimate of period, phase and amplitude. The JTK p-value is the estimated probability of rejecting the null hypothesis. Here the null hypothesis is a dataset that is not rhythmic. A threshold of p b 0.05 was used to identify rhythmicity The JTK q-value is the false discovery rate at which a gene is called cyclic. For further details see Hughes et al. (2010) [43] . We selected sample size for murine studies based on the numbers typically reported in the literature. (Fig. 1A) . The amplitude of mean arterial pressure (MAP) in Clock Δ19/Δ19 mice is also blunted in the light period (murine sleep time) (Fig. 1B) . Diurnal profile is shown on the left, and the light and dark phase quantification of MAP is shown on the right (Fig. 1B) . These activity and MAP observations are consistent with those previously reported in Clock Δ19/Δ19 mice [2, 20] ; however this affects the heart with aging has not been previously investigated. Thus we next looked at cardiovascular parameters.
Results
Clock
To investigate the role of Clock in cardiac structure and function we first examined age-dependent changes in heart weight (HW). HW was significantly greater in the Clock Δ19/Δ19 mice by 18 months of age as compared to Clock Δ19/+ and WT mice (Fig. 1C) . Moreover, HW:body weight and HW:tibia length were also significantly greater by 18 months of age compared to Clock Δ19/+ and WT mice (Fig. 1D ).
These observations are consistent with the notion that the Clock Given that Clock underlies age-dependent changes in heart structure we next examined how these correlated with cardiac functional outcomes. First cardiac structure and function were examined using serial echocardiography from 4 to 21 months of age. Compared with the WT and Clock Δ19/+ mice, Clock Δ19/Δ19 mice had greater adverse remodeling with significantly increased left ventricular (LV) dimensions by 12 months of age, followed by decreased ejection fraction (%EF) and fractional shortening (%FS) ( Fig. 2A -C, and Table 1 ). Because the differences in the Clock Δ19/Δ19 mice could be correlated to cardiovascular hemodynamic responses, we next measured these in vivo. We found that aging Clock Δ19/Δ19 mice showed worse functional profiles in LV endsystolic and LV end-diastolic and arterial pressures ( Fig. 2D , and Table 2 ). Concurrent with a drop in MAP, is reduced total peripheral resistance (TPR) and impaired myogenic tone (Fig. 2E, Table 2 , and Supplementary Fig. 1 ). The disease phenotype is restricted to the aging Clock Δ19/Δ19 mice. The young animals do not develop pathology, nor impaired cardiac function and appear healthy, with all cardiovascular parameters similar to the WT and Clock Δ19/+ littermates. The heart disease that develops in the aging Clock Δ19/Δ19 animals does so only over an extended period time, and the cardiac and vascular systems decompensate with age.
Dysregulation of miRNA expression in Clock Δ19/Δ19 hearts
Since Clock is a transcriptional regulator of the core circadian mechanism [22] , we next evaluated the effects on gene expression in the heart. Clock drives Per2 expression, and Clock Δ19/Δ19 hearts haves significantly reduced Per2 amplitude by JTK_CYCLE (Fig. 3A) . Second, Clock also drives Rev-Erbα, and Clock Δ19/Δ19 hearts have reduced Rev-Erbα expression in the heart (Fig. 3A) . Lastly, since Rev-Erbα is a key repressor of Bmal1 and Clock, we anticipated and found that Clock Δ19/Δ19 hearts have increased expression of these genes ( Fig. 3A ) [44, 45] . The statistical outcomes for the JTK_CYCLE analyses are in Supplementary Table 1 . Thus these data show that Clock underlies the diurnal cycling of the circadian mechanism genes, which in turn are postulated to drive the output of genes and proteins important for the heart [1, 3, 17, 18] . The core circadian mechanism genes drive the output of a wide variety of mRNAs. These mRNAs in turn have an important role in producing proteins in the heart. Up to~13% of the mRNAs [18] and 8% of the proteins [3] in the heart exhibit diurnal rhythms. Many of these products are involved in key cellular processes in the heart; time of day of expression is important for heart structure and function [5, 15] . Moreover, it has been shown that miRNAs also influence cardiac growth pathways and renewal pathways in the heart [ at www.circadianmicrorna.com. Hierarchical cluster analysis (Fig. 3C ) and functional mapping (Fig. 3C , and Supplementary Table 3) revealed that the greatest number of target genes of the altered miRNAs in Clock-Δ19/Δ19 hearts were involved in the PTEN-Akt signalling pathway. For example, primary transcripts from the miR-17-92 family and their cognate miRNAs are negative regulators of PTEN [48, 49] ; we found that this family of miRNAs are have reduced expression in young Clock Δ19/Δ19 hearts (Fig. 3D, E) . Moreover, these miRNAs do not oscillate with respect to time-of-day in WT hearts. In addition, there are no oscillations in Clock Δ19/Δ19 hearts. However, all of the miRNAs were significantly reduced in Clock Δ19/Δ19 hearts at virtually all time points over the day night cycle (ZT, 3, 7, 11, 19, 23 ) as compared to WT hearts (Supplementary Fig. 2 ). Finally, these miRNAs exhibit age-dependent increased expression by 21 months of age (Fig. 3F, G) . Thus Clock plays a role in expression of regulatory miRNAs that target the PTEN-AKT pathway in the heart. 
Disruption of AKT signalling in Clock Δ19/Δ19 hearts
Given the significant relationship between miRNAs and the PTEN-AKT pathway, we next investigated whether Pten mRNA was rhythmically expressed in the heart. As rhythmic Pten expression has not yet been shown in the heart we next determined whether expression is rhythmic and driven by the endogenous circadian mechanism independent of the light:dark cycle. We found a significant circadian rhythm in Pten mRNA in WT hearts under constant darkness (JTK p-value = 4.2 × 10 −3 ) (Fig. 4A) . Furthermore, we determined whether expression is rhythmic under the normal light:dark conditions that animals and humans live under. We found a significant rhythm in Pten mRNA in WT hearts in the diurnal environment (JTK p-value = 0.02) (Fig. 4B) , In contrast to the results in our WT animals, Pten mRNA expression exhibits a loss of rhythmic oscillation, as well as increased levels over 24 h in Clock Δ19/Δ19 hearts (Fig. 4A, B) . The statistical outcomes for JTK-CYCLE analyses are in Supplementary Table 4 . Next, we investigated if PTEN protein exhibits a diurnal rhythm in the heart, by western blot (Fig. 4C) . We found that PTEN protein abundance is rhythmic in WT hearts (JTK p-value = 0.038) (Fig. 4D) . Given that PTEN is rhythmic in the WT heart, we next investigated the profiles in Clock Δ19/Δ19 hearts. PTEN protein abundance exhibits a loss of rhythmic oscillation (JTK p-value = 1.00), as well as increased levels over 24 h in Clock Δ19/Δ19 hearts, as compared to WT hearts (Fig. 4C, D) . In contrast, phospho-PTEN abundance did not oscillate in WT or Clock-Δ19/Δ19 hearts over 24 h periods ( Fig. 4C and Supplementary Fig. 3 ).
Taken together these results indicate that PTEN oscillations occur at the level of the protein.
Given that PTEN is a negative regulator of AKT (S473) phosphorylation, we next investigated whether our findings correlated with changes in downstream phospho-AKT expression (Fig. 4E) . We found that in WT hearts, AKT exhibited rhythmic phosphorylation (JTK p-value = 0.026) with increased levels during the dark phase (animals asleep). In Clock-Δ19/Δ19 hearts, there was a loss of rhythmic phosphorylation (JTK pvalue = 1.00), and blunted phospho-protein levels during the dark phase (Fig. 4F) . Moreover, when we plot Clock Δ19/Δ19 PTEN values over the light (animals asleep) or dark (animals awake) period, we see a loss of diurnal rhythms with increased levels of PTEN in the dark (Fig. 4G) . Conversely, there is a loss of diurnal rhythms for phospho-AKT, and reduced levels in the dark (Fig. 4H) . Thus although the timeof-day changes are interesting, it is also worth noting that these occur over many days and weeks, which could be a driving factor underlying the structural changes that develop in the Clock Δ19/Δ19 hearts.
In light of these observations, we next performed a series of experiments using young Clock Δ19/Δ19 mice and found a significant cascade effect. PTEN is the main negative regulator of downstream AKT signalling. Increased PTEN abundance in young Clock Δ19/Δ19 hearts was associated with reduced AKT activation and a loss of AKT (S473) phosphorylation rhythms inClock Δ19/Δ19 hearts ( Fig. 4E-H) . Two direct downstream targets of AKT namely GSK-3β (S9) and PRAS40 (T246), as well as the indirect target S6K1 (T389), also showed a loss of diurnal rhythms in phosphorylation in Clock Δ19/Δ19 hearts consistent with an altered signalling cascade (Fig. 4I) . The rhythmic JTK_CYCLE values are in Supplementary Table 5 .
Clock Δ19/Δ19 cardiomyocytes and hypertrophy
We next studied the effects of the Clock Δ19/Δ19 mutation on AKTsignalling and cardiac growth using neonatal cardiomyocytes (Fig. 5A ). FBS is a general activator of cell growth [40] and treatment stimulated both WT and Clock Δ19/Δ19 cardiomyocytes to increase to similar cell size (Fig. 5B) .However, the Clock Δ19/Δ19 cells were smaller compared to WT cells and thus showed a greater fold-change from baseline (Fig. 5C ). IGF-1, a potent activator of AKT-signalling [50] , increased cell size in WT but not Clock Δ19/Δ19 cardiomyocytes, consistent with impaired AKT-activation in these cells (Fig. 5D ). Conversely LiCl stimulated the growth of Clock Δ19/Δ19 cardiomyocytes, consistent with LiCl-mediated inactivation of the elevated GSK-3β activity in these cells (Fig. 5E ). These data provide further support that Clock is a key regulator of the AKT signalling axis regulating cardiomyocyte growth pathways. One key element of the studies in Fig. 5 was to examine how a known AKT activator (IGF-1) influences cardiac hypertrophy in Clock-Δ19/Δ19 cardiomyocytes. However, since we are interested in expression of the miRNAs in the intact animal in vivo, we also assessed expression of the miR-17-92 family in Clock Δ19/Δ19 and WT hearts from P0 mice LVIDd; left ventricle internal dimensions at diastole, LVIDs; LV internal dimensions at systole, FS; fractional shortening, EF; ejection fraction, IVSd; septal wall thickness at diastole, PWTd; posterior wall thickness at diastole, LV; left ventricle, BW; body weight, HR, heart rate. n = 9/group, ⁎ p b 0.05 vs. all other groups of same age; ⁎⁎ p b 0.01 vs. all other groups of same age as calculated by two way ANOVA followed by Tukey post hoc. Significant age and genotype effects were identified for all parameters measured. Values are mean ± SEM.
(the same day at which cells are collected for culture). We found increased expression of all miR-17, miR-18a, miR-19b, miR-20a, and miR-92a in Clock Δ19/Δ19 compared to WT hearts (Fig. 5F ). Expression of these miRNAs more resembles aged Clock Δ19/Δ19 hearts consistent with the notion that during disease states the heart reactivated fetal like features.
Increased AKT signalling in aged Clock
Δ19/Δ19 hearts Chronic dysregulation of AKT signalling causes maladaptive cardiac remodeling [51] . Thus we next assessed AKT signalling in aged (21 month old; ZT07) Clock Δ19/Δ19 versus WT mice. We observed that phosphorylation of AKT (S473) and its downstream targets S6K1 (T389) and GSK-3β (S9) were increased in the old Clock Δ19/Δ19 hearts (Fig. 6A ). In the aged Clock Δ19/Δ19 mice, chronic Clock disruption led to increased activation of AKT signalling pathways leading to inactivation of GSK-3β, consistent with the development of cardiac hypertrophy in these animals. Importantly, GSK-3β S9 phosphorylation also occurs in failing human hearts [52, 53] , and this is consistent with the development of reduced cardiac function (Fig. 2) and increased gene expression of the heart failure (HF) biomarkers Nppa and Nppb in the old Clock Δ19/Δ19 hearts (Fig. 6B) .
Pharmacological modulation and hypertrophy
We next sought to examine whether modulation of the circadian mechanism downstream of Clock, using the REV-ERB agonist SR9009 [54] , is efficacious in our model. We found that SR9009 increased oxygen consumption in the aged WT mice (Fig. 6C) , consistent with effects observed in young mice [54] . Interestingly, SR9009 also increased oxygen consumption in the old Clock Δ19/Δ19 mice (Fig. 6D) . Although not as severe as the Clock Δ19/Δ19 mice, old WT mice also have increased heart size and decreased cardiac function by 21 months of age ( Figs. 1  and 2 ). Therefore we further tested whether pharmacological modulation in mice with a functional Clock gene could alter AKT activation consistent with our hypothesis. First we show that SR9009 is effective at altering circadian mechanism function in WT mice as Bmal1 and Reverbα mRNA expression were reduced in the hearts mice treated with SR9009 compared to vehicle treated mice (Fig. 6E) . Moreover, we show that SR9009 reduced AKT (S473) activation in WT hearts (Fig. 6F) , while AKT activation was not reduced in Clock Δ19/Δ19 hearts (Fig. 6G) . Furthermore, there is a concurrent up-regulation of Atrogin-1 in the hearts SR9009 treated WT mice (Fig. 6H (which inhibits AKTdependent cardiac hypertrophy [55] ) and a reduction in heart weight ( Fig. 6I) . To assess whether agonist treatment has a direct effect on cardiac size we used the TAC model. We found that SR9009 significantly reduced LVIDd (Fig. 6J) , HW (Fig. 6K) , and HW:BW ratio (Fig. 6L) compared to vehicle treated TAC mice. This was not associated with a reduction in blood pressure as measured by in-vivo hemodynamics (Supplementary Table 7 ). In sham mice SR9009 did not affect any morphometric, echocardiographic, or in-vivo hemodynamic parameters supporting that reduction of cardiac hypertrophy was specific to the TAC mice. Collectively these results suggest that SR9009 acts directly to reduce cardiac hypertrophy, consistent with our findings in aged WT mice.
Discussion
Here we investigated the role of (and Supplementary Table 2) , n = 3 hearts/group. (C) Hierarchal cluster analysis of pathways targeted by differentially expressed miRNAs using miRPath. KEGG identifications are in Supplementary Fig. 3 . Expression of (D) the primary miR-17-92 transcript, and (E) the mature miRNAs in 4 month old Clock
Δ19/Δ19
hearts, and (F) up-regulation of the primary miR-17-92 transcript and (G) and mature miRNAs, by 21 months of age, n = 3 hearts/group, ⁎ p b 0.05 by Students t-test. Values are mean ± SEM.
to the development of age-dependent cardiovascular disease. Clock Δ19/Δ19 mice develop increased heart weight, cardiomyocyte hypertrophy and interstitial fibrosis by 21 months of age, compared to WT littermates. Moreover, aging Clock Δ19/Δ19 mice exhibit LV remodeling characterized by increased LV dilation and reduced function by echocardiography and in-vivo hemodynamics analyses. In order to investigate the underlying molecular changes we first examined microRNA expression in the heart. We found that a loss of Clock reduces expression of the primary transcript and mature miRNAs of the miR-17-92 family, which plays an important role in PTEN-AKT signalling. Consistent with these, changes in miRNA expression, Clock Δ19/Δ19 mice have altered diurnal activation of PTEN-AKT pathway genes and proteins. To further establish circadian regulation of AKT signalling we used both in-vitro and in-vivo approaches. We show a direct functional consequence in neonatal cardiomyocytes, as hypertrophy responses were impaired in Clock Δ19/Δ19 cardiomyocytes treated with the AKT activator IGF-1.
Moreover, we show pharmacological inhibition targets to this pathway in vivo as SR9009 reduced cardiac AKT activation in functional WT but not the impaired Clock Δ19/Δ19 mice. This is consistent with the notion that the Clock gene is required for SR9009 to modulate AKT activation. Collectively, these results demonstrate that Clock plays an important role in normal cardiovascular aging and that the Clock mutation leads to age-dependent cardiovascular disease.
Although it is well established that circadian rhythms play a role in the timing of onset of adverse cardiovascular events [4, 5, [56] [57] [58] , their role in cardiac aging is poorly understood. Here we showed that disturbing Clock leads to the development of age-dependent heart disease. This is consistent with our earlier experimental paradigm showing that altering the circadian mechanism through genetic or environmental disturbances exacerbates existing heart disease. For example, disturbing rhythms exacerbates cardiac remodeling after myocardial infarction in mice; maintaining rhythms benefits infarct healing and outcome [33] . In addition, circadian rhythm disruption reduces hypertrophic responses and impairs cardiac function in mice subjected to pressure-overload induced cardiac hypertrophy [10] . At the molecular level, disruption of the circadian clock alters cardiac gene rhythms [1, 3, 10] , protein abundance [3] , and cardiomyocyte function [19] . Thus the circadian mechanism is vital for normal cardiovascular function, and disturbing the mechanism factor Clock is consistent with altered gene and protein profiles leading to disturbed cardiomyocyte function and the development of cardiovascular disease. In our study, the aged Clock Δ19/Δ19 mice have cardiovascular disease at multiple levels, including cardiac hypertrophy, fibrosis, reduced % ejection fraction and % fraction shortening, decreased contractility, and reduced myogenic responsiveness. Previously Martin Young and colleagues reported that cardiomyocyte specific Clock mutant (CCM) mice develop age-dependent cardiac hypertrophy and fibrosis but not contractile dysfunction [11] . This is consistent with our findings that the circadian mechanism regulates key components of cardiomyocyte growth pathways. In addition, our data suggest that the pathogenesis and pathophysiology of age-dependant cardiomyopathy depends disruption of the circadian mechanism at multiple levels including heart and vasculature. The circadian mechanism in the vasculature and plays a role in vascular structure and function [57, 59, 60] ; future studies investigating the interaction between the heart and regulation of myogenic response and vascular tone are worthy of investigation. Our data further demonstrate that Clock plays a direct role in cardiac miRNA expression as loss of Clock changes the profiles in the heart, especially those related to cardiac growth and renewal pathways. Importantly, we found altered expression of the miR-17-92 family in Clock Δ19/Δ19 hearts. This miRNA family is important for cardiac structure and function, as experimentally transgenic overexpression induces cardiomyocyte proliferation and is associated with lethal cardiomyopathy and arrhythmogenesis in mice [48, 61] .
In terms of mechanism, we observed changes downstream of miR-17-92 in Clock Δ19/Δ19 mice including altered phosphorylation patterns and blunted activation of AKT, GSK3β, PRAS40 and S6K1; these are all components of the PTEN-AKT signalling pathway regulating cardiac hypertrophy. Intriguingly, loss of Clock specifically in cardiomyocytes alters phosphorylation patterns of AKT and GSK-3β [62] , Moreover, altering activation of AKT and its downstream mediator mTOR [51] , or inhibition of GSK-3β [63] , directly targets cardiac hypertrophy in vivo. It's worth noting that Clock disruption on this pathway occurs on a daily basis, and also occurs over many days, weeks, and years to lead to heart disease. This is consistent with the notion that increased AKT signalling is linked to maladaptive remodeling when activated on a long term basis [51, 53] . Thus, there could be an uncoupling of AKT regulation due to disease pathways being activated with age as part of the remodeling process. Collectively, these studies demonstrate a key role for Clock in regulating cardiac growth, and disruption is associated with exacerbation of hypertrophy pathways with aging.
In the future it would be interesting to look at the relative contributions of the period misalignment caused by the Clock mutation vs. impaired CLOCK mediated transcription in the development of agedependent cardiomyopathy. In addition, determining the role of other core circadian factors in cardiac aging, especially those that have been shown to play a role in disease pathophysiology warrants future investigation [9, 34, [64] [65] [66] [67] . Notably, it will be important to determine whether these core circadian factors mediate cardiac aging through circadian or circadian-independent pathways. Identifying the role of circadian mechanism factors in aging could have therapeutic implications, especially for individuals subjected to circadian rhythm disturbance (e.g. shift work, sleep disorders) in the aging population.
In terms of clinical implications, disturbed circadian rhythms in humans are associated with increased risk of heart disease and worse outcomes [68] [69] [70] . For patients with heart failure, a major concern is impaired oxygen consumption, in part because it's a limiting factor for rehabilitory exercise [71] . Notably, we found that pharmacological targeting of the circadian mechanism using the agonist SR9009 improved oxygen consumption in our old animals. This drug has also been shown to increase oxygen consumption and exercise capacity in healthy young mice [54, 72] , and is aimed to improved skeletal muscle performance related to sports endurance [73] . We also found that SR9009 attenuates cardiac hypertrophy in TAC mice, consistent with our findings that the circadian mechanism plays a key role in regulating cardiac growth pathways. This could also open new doors for reducing cardiac hypertrophy in patients with heart disease. It is worth nothing that we gave the drug twice daily for effect, based on the original identification of SR9009 [54] . Recent studies have suggested that there could be an optimal time for dosing during the light period [74] ; this might be worthy of consideration especially if drugs targeting the circadian mechanism move towards clinical translation. Future studies using pharmacological targeting of the circadian mechanism can open new avenues to treat cardiovascular patients.
Conclusions
In summary, Clock Δ19/Δ19 mice develop cardiac hypertrophy. In Clock Δ19/Δ19 mice there is dysregulation of the core circadian gene mechanism, output genes and miRNA post-transcriptional regulators. Functional mapping identified the PTEN-AKT signalling pathway as targets of Clock-induced cardiac hypertrophy. Although other miRNA pathways may also be involved, our results indicate that Clock is a key regulator of AKT signalling for triggering cardiac hypertrophy in vivo. These experiments demonstrate that there is novel potential for targeting the circadian mechanism to reduce cardiac hypertrophy; Investigating strategies are a promising new area for treating patients with heart disease.
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